Sovereign Nations. Different Laws. One Complicated Payments System.
Sovereign Nations. Different Laws. One Complicated Payments System. On Indigenous Peoples' Day, it's time to examine why tribal gaming, ...
The Food and Drug Administration's recommendation to classify 7-hydroxymitragynine (7-OH) as a controlled substance has intensified state-level debates about kratom regulation, with Nevada, California, and other states examining how to address synthetic kratom compounds while natural kratom products remain legally accessible.
Nevada currently permits kratom sales to individuals over 18 years old, with requirements for proper labeling and testing standards but limited oversight of product formulations. The emergence of 7-OH, which the FDA characterizes as 13 times more potent than morphine, has created regulatory gaps that concern both health officials and legitimate kratom retailers.
David Marlon, CEO and founder of Las Vegas nonprofit Vegas Stronger, reports increasing synthetic kratom use among clients seeking mental health and substance abuse resources. "There's a new form of synthetic kratom that's come out, and it's many times more potent than the actual leaves that are sold in markets," Marlon stated. He reports seeing hundreds of kratom users across various socioeconomic backgrounds, from unhoused individuals to professionals.
The accessibility of kratom products through gas stations, smoke shops, and other retail locations without education requirements for sellers raises questions about consumer safety and informed use. Marlon noted, "If you allow something that is physiologically addicting to be sold, over time it is going to increase as more people use it and more people get addicted."
Natural Life owner Anja Wenzel in Henderson, Nevada, distinguishes between natural kratom products and synthetic 7-OH formulations. Her store exclusively sells natural kratom products, refusing to carry synthetic compounds. "I feel it is very dangerous and it can have a big impact, and there needs to be more regulation for smoke shops and gas stations selling these products without any education or transparency on what they're selling to the customer," Wenzel explained.
Wenzel reports serving elderly customers with chronic pain conditions seeking alternatives to opioid medications. "Many of them have severe pain issues and have been using opioids and don't want to use them anymore because it turns them into vegetables or they get addicted to them," she stated. Her approach includes educating customers on appropriate dosing to prevent misuse.
The distinction between natural kratom containing low levels of 7-hydroxymitragynine and concentrated synthetic formulations marketed as standalone products remains a central point in regulatory debates. Natural kratom advocates argue that conflating these categories could eliminate access to products that users find beneficial for pain management and opioid reduction.
Nevada legislators attempted to expand state oversight of kratom products in 2023 through Assembly Bill 322, which would have required products to be registered with the Division of Public and Behavioral Health. Governor Joe Lombardo vetoed the legislation, citing the lack of FDA-approved uses for kratom.
The veto reflects broader tensions in state kratom regulation between implementing consumer protections and avoiding legitimizing products without federal approval. Questions remain about whether states should regulate products that federal agencies have not approved for any medical use, and whether state oversight implies endorsement of controversial substances.
Nevada's current regulatory framework provides age restrictions and labeling requirements but lacks mechanisms to distinguish between natural kratom products and synthetic concentrated compounds like 7-OH. The absence of registration requirements means state health officials have limited visibility into which products are being sold and their formulations.
Kratom regulation varies significantly across states, creating a patchwork of legal frameworks. Six states have banned kratom entirely: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. Several other states have implemented age restrictions, labeling requirements, or county-level bans.
Some states have adopted the Kratom Consumer Protection Act (KCPA), which establishes product standards, testing requirements, and age restrictions while keeping kratom legal. States with KCPA legislation include Arizona, Georgia, Nevada, and Utah. These frameworks attempt to balance access with consumer protection by requiring manufacturers to register with state authorities and meet quality standards.
Other states are considering legislation in response to the FDA's actions on 7-OH. California lawmakers have discussed bills addressing synthetic kratom compounds specifically, attempting to regulate concentrated formulations differently from natural kratom products. The outcome of these efforts could provide models for other states facing similar regulatory questions.
The FDA's recommendation to schedule 7-OH as a controlled substance creates potential conflicts with state regulatory approaches. If the DEA classifies 7-OH as a Schedule I controlled substance, it would become illegal nationwide regardless of state laws. However, the classification's impact on natural kratom products containing low levels of 7-OH remains unclear.
States that have invested in regulatory frameworks for kratom products may find their systems disrupted if federal scheduling effectively prohibits products they have attempted to regulate for safety. The question of whether natural kratom products would remain legal if their chemical constituent 7-OH is scheduled has not been definitively answered.
Some state regulators express concern that federal prohibition without distinction between synthetic concentrated products and natural kratom could eliminate access for individuals using kratom to manage chronic conditions or reduce opioid dependence. Others view federal scheduling as necessary to prevent another substance use crisis.
State-level discussions reflect broader debates about harm reduction versus prohibition approaches to substance regulation. Advocates argue that regulatory frameworks with testing standards, age restrictions, and consumer education requirements better serve public health than outright bans that drive users to unregulated markets.
Marlon's observations about kratom use spanning socioeconomic groups suggest that prohibition could affect diverse populations differently. Professional users with chronic pain conditions might seek products through different channels than individuals experiencing homelessness dealing with substance use disorders.
The synthetic kratom proliferation that concerns both regulators and natural product advocates illustrates challenges in controlling chemical modifications of plant-based supplements. As manufacturers create concentrated or modified compounds to enhance effects, regulatory systems designed for natural products may prove inadequate.
If the DEA schedules 7-OH as recommended by the FDA, states will face implementation questions about enforcement, product testing, and distinguishing between legal and illegal kratom formulations. Retailers selling natural kratom products will need clarity about whether their inventory complies with federal law.
Testing infrastructure to identify and quantify 7-OH concentrations in products may require development, creating costs for state regulatory agencies and manufacturers. States without robust testing programs may struggle to enforce distinctions between natural and synthetic products if both remain legally available at state level while 7-OH is federally controlled.
The timeline for these changes remains uncertain. The DEA's review process following FDA recommendations typically spans months, providing some window for states to consider how federal scheduling will interact with their regulatory frameworks.
As state and federal kratom regulations diverge and evolve, businesses in the supplement industry face increasingly complex compliance requirements across multiple jurisdictions. Qredible's Q-Trust quality management system provides real-time regulatory monitoring across all 50 states, automated compliance tracking for changing requirements, and comprehensive documentation systems that adapt to both state and federal regulatory frameworks. Contact our team to learn how our multi-jurisdictional compliance solutions can help your business maintain product quality and regulatory compliance as kratom regulations continue to develop at state and federal levels.
